No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Women with a Genomic Grade Index High-Risk ER-positive, HER2-negative Breast Cancer By Ogkologos - August 19, 2025 611 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ASTER 70s study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Neoadjuvant Nivolumab Plus Chemotherapy Improves OS Among Patients with Resectable NSCLC... June 24, 2025 New Treatment Combinations Slow Progression of Prostate Cancer and Stomach and... February 5, 2024 Persistent Poverty Linked to Increased Risk of Dying from Cancer November 19, 2020 FDA Grants Accelerated Approval to fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic... April 12, 2024 Load more HOT NEWS Great Oaks Grow From Small Acorns Oncology Is Committed to Doing... FDA Proposes Rule Prohibiting Menthol Cigarettes EMA Recommends Extension of Indications for Cabozantinib European Lung Cancer Congress 2025, Paris, France, 26-29 March 2025
